vs
Apollo Commercial Real Estate Finance, Inc.（ARI）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Apollo Commercial Real Estate Finance, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.0倍（$73.3M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 39.9%，领先344.2%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 4.0%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -4.6%）
阿波罗商业房地产金融公司是一家房地产投资信托企业，主要发起、收购并管理商业地产债务资产，包括优先抵押贷款、夹层贷款及商业抵押贷款支持证券，主营美国市场，致力于为投资者创造稳定收益。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ARI vs RIGL — 直观对比
营收规模更大
ARI
是对方的1.0倍
$69.8M
营收增速更快
RIGL
高出17.2%
4.0%
净利率更高
RIGL
高出344.2%
39.9%
两年增速更快
RIGL
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.3M | $69.8M |
| 净利润 | $29.2M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 39.7% | 33.2% |
| 净利率 | 39.9% | 384.0% |
| 营收同比 | 4.0% | 21.2% |
| 净利润同比 | -28.2% | 1769.2% |
| 每股收益（稀释后） | $0.19 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARIRIGL
| Q4 25 | $73.3M | $69.8M | ||
| Q3 25 | $61.6M | $69.5M | ||
| Q2 25 | $70.9M | $101.7M | ||
| Q1 25 | $65.8M | $53.3M | ||
| Q4 24 | $70.5M | $57.6M | ||
| Q3 24 | $71.6M | $55.3M | ||
| Q2 24 | $81.1M | $36.8M | ||
| Q1 24 | $80.5M | $29.5M |
净利润ARIRIGL
| Q4 25 | $29.2M | $268.1M | ||
| Q3 25 | $50.8M | $27.9M | ||
| Q2 25 | $20.7M | $59.6M | ||
| Q1 25 | $26.0M | $11.4M | ||
| Q4 24 | $40.7M | $14.3M | ||
| Q3 24 | $-91.5M | $12.4M | ||
| Q2 24 | $35.8M | $-1.0M | ||
| Q1 24 | $-104.5M | $-8.2M |
毛利率ARIRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率ARIRIGL
| Q4 25 | 39.7% | 33.2% | ||
| Q3 25 | 82.8% | 40.9% | ||
| Q2 25 | 29.4% | 60.1% | ||
| Q1 25 | 39.7% | 23.9% | ||
| Q4 24 | 57.9% | 28.9% | ||
| Q3 24 | -127.8% | 25.4% | ||
| Q2 24 | 44.2% | 1.2% | ||
| Q1 24 | -129.6% | -23.6% |
净利率ARIRIGL
| Q4 25 | 39.9% | 384.0% | ||
| Q3 25 | 82.4% | 40.2% | ||
| Q2 25 | 29.3% | 58.6% | ||
| Q1 25 | 39.5% | 21.5% | ||
| Q4 24 | 57.7% | 24.9% | ||
| Q3 24 | -127.9% | 22.5% | ||
| Q2 24 | 44.1% | -2.8% | ||
| Q1 24 | -129.8% | -27.9% |
每股收益（稀释后）ARIRIGL
| Q4 25 | $0.19 | $14.11 | ||
| Q3 25 | $0.34 | $1.46 | ||
| Q2 25 | $0.12 | $3.28 | ||
| Q1 25 | $0.16 | $0.63 | ||
| Q4 24 | $0.25 | $0.82 | ||
| Q3 24 | $-0.69 | $0.70 | ||
| Q2 24 | $0.23 | $-0.06 | ||
| Q1 24 | $-0.76 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $139.8M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $1.9B | $391.5M |
| 总资产 | $9.9B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ARIRIGL
| Q4 25 | $139.8M | $155.0M | ||
| Q3 25 | $245.9M | $137.1M | ||
| Q2 25 | $177.6M | $108.4M | ||
| Q1 25 | $166.4M | $77.1M | ||
| Q4 24 | $317.4M | $77.3M | ||
| Q3 24 | $194.3M | $61.1M | ||
| Q2 24 | $174.7M | $49.1M | ||
| Q1 24 | $161.2M | $49.5M |
总债务ARIRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益ARIRIGL
| Q4 25 | $1.9B | $391.5M | ||
| Q3 25 | $1.9B | $117.6M | ||
| Q2 25 | $1.8B | $81.9M | ||
| Q1 25 | $1.9B | $18.6M | ||
| Q4 24 | $1.9B | $3.3M | ||
| Q3 24 | $1.9B | $-14.6M | ||
| Q2 24 | $2.0B | $-29.9M | ||
| Q1 24 | $2.0B | $-31.7M |
总资产ARIRIGL
| Q4 25 | $9.9B | $513.6M | ||
| Q3 25 | $9.5B | $242.5M | ||
| Q2 25 | $9.8B | $206.7M | ||
| Q1 25 | $8.8B | $176.0M | ||
| Q4 24 | $8.4B | $164.0M | ||
| Q3 24 | $9.1B | $139.4M | ||
| Q2 24 | $9.3B | $128.4M | ||
| Q1 24 | $9.2B | $126.5M |
负债/权益比ARIRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.5M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 4.88× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ARIRIGL
| Q4 25 | $142.5M | $22.0M | ||
| Q3 25 | $31.7M | $24.0M | ||
| Q2 25 | $63.2M | $30.5M | ||
| Q1 25 | $39.3M | $-893.0K | ||
| Q4 24 | $200.3M | $14.5M | ||
| Q3 24 | $47.2M | $21.7M | ||
| Q2 24 | $50.2M | $302.0K | ||
| Q1 24 | $52.8M | $-5.0M |
现金转化率ARIRIGL
| Q4 25 | 4.88× | 0.08× | ||
| Q3 25 | 0.62× | 0.86× | ||
| Q2 25 | 3.05× | 0.51× | ||
| Q1 25 | 1.51× | -0.08× | ||
| Q4 24 | 4.93× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
